Quantcast
Close Window
   
Welcome :o)
Welcome to another year exposing the harms of Johnson & Johnson products and the executives that care more about money than human health...
 
There really is a highly effective way to put an end to mass tort lawsuits: GET JOHNSON & JOHNSON AND SUBSIDIARY KNOWN DEFECTIVE, HARMFUL AND/OR TOXIC PRODUCTS OFF THE GLOBAL MARKET
 
This work is 100% independent. I am NOT a victim, NOT a lawyer, NOT paid by anyone other than visitors to the site. And no, I do not own any stock in Johnson & Johnson.
 
Emily.
HomeAbout

Content List
100+ articles of harm and corruption by Johnson & Johnson and subsidiary products.
Click for content list...

Glad to see you :o)
Latest Content: April 8, 2017...
2017 Johnson and Johnson US Lawsuit Update: Jump from 76,400 to 104,700 (2017, April 8)
Yet another year of a dramatic increase in lawsuits against Johnson & Johnson and subsidiaries in a lot of countries over a variety of products, and don't include many products with legal action pending.
levaquin, risperdal, asr, transvaginal, tvt, mesh, lawsuit, investor
 
March 2017 marked FIVE YEARS of work exposing harm, corruption and massive costs of flood of KNOWN HARMFUL Johnson & Johnson products.
 
NOTICE: DUE TO HOMELESSNESS, I DO NOT HAVE ANY MONEY TO PUT TOWARDS THIS PROJECT.
 
Site saved again by a woman in the United Kingdom. Thank you VERY much!
 
This web site currently has the attention of:
click link to validate IP address through whatismyipaddress.com
 
US GOVERNMENT:
US Senate
US Department of Defense
US Department of Justice
US Homeland Security
 
GLOBAL FINANCIAL INSTITUTIONS:
...including many Johnson & Johnson shareholders ;o)
 
Vanguard
The Bank of New York Mellon Corp
Lloyds Banking Group PLC
Royal Bank of Canada
Bank of America
Harris Trust & Savings Bank
Deutsche Bank
Macquarie Bank
PNC Bank
Crédit Agricole Bank
Royal Bank of Scotland
Raymond James Financial
BlackRock Financial Management
...and many, many more from all over the world ;o)
 
I am not paid by lawyers, doctors, etc - ONLY by visitors to the web site, the PEOPLE I am working for, PEOPLE like you. Currently reduced to only a part-time job, I donate the remainder of my time to take care of all the work involved in maintaining the site by doing the research, search engine optimized content, responding to victim emails and social media to create awareness among consumers to prevent new injuries as well as continue increasing awareness among Johnson & Johnson shareholders and global health organizations. Feel free to browse list of notable visitors to the web site.
 
So far April raised a TOTAL of:
$50 April 1 from US
$50 April 11 from UK
$100 TOTAL (it's not a wonder I'm starving on the streets of homeless hell, eh?)
 
God Bless You and Yours and keep you safe from harm,
Emily
 
Please send financial support to keep this very important GLOBAL consumer safety effort going...
 
Enter any amount in GiftBox below or PayPal to Email:
 
emily@johnsonandtoxin.com
 
$.00   
 
Sponsored in part by...
Examining Medicine An in-depth comprehensive, frequently updated look at extreme risks and permanent brain damage caused by psychiatric drugs.
----- / / -----
Fiddaman Blog Bob Fiddaman has been writing about the dangers of antidepressants since 2006. In 2011 he was presented with two human rights awards from the Citizens Commission on Human Rights.
----- / / -----
Special Needs Advocate Power Join me as we work hard to ensure what our very special children need.

Xarelto by Johnson & Johnson is Likely Another OverHyped Dud
Here we go again - another supposed blockbuster drug with issues but will get pushed through FDA anyway.

Keywords: xarelto, FDA, clinical, trial, risk, blockbuster, johnson & johnson, johnson and johnson
Date Created/Edited: May 23, 2012
 

Special Sections....
 
Mesh Files
Baby Powder (talc) Files
Risperdal Files
Levaquin Files
Xarelto Files
Hips Files
Letters to Shareholders
SEC Lawsuits Files

 
Recent Content....
Why President Trump Should Shut Down US FDA (2017, March 28)
Healthcare organizations around the world depend on US FDA decisions, however, profit, rather than safety, seems to be the primary motivation.
healthcare, health, obamacare, donald, trump, fda, fraud, kickback
 
The Fastest Growing Segment of Johnson & Johnson Is... (2016, November 15)
Growing over 29% in 2016, this is definitely the fastest growing segment of Johnson & Johnson!
johnson & johnson, J&J, JNJ, 2016, lawsuit, lawsuits, tort, liability
 
Third Quarter 2016 Lawsuits Against Johnson & Johnson Still Exploding! Now 99,000! (2016, November 15)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 99,000.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
The Difference Between Guinea Pig and Cash Cow (2016, September 27)
People keep saying pharma is using us as 'guinea pigs'. Uh, not quite. Take a minute to learn the difference between a 'guinea pig' and a 'cash cow'.
guinea pig, immunization, vaccination, profit, harm, autism, disability, asthma
 
Johnson & Johnson Victims at Risk of RE-Victimization (2016, August 22)
If you are currently a victim of a known harmful Johnson & Johnson subsidiary product and have high medical needs due to your injuries, you are at increased risk of becoming a victim of another known harmful Johnson & Johnson subsidiary product.
jnj, johnson and johnson, johnson & johnson, victim, mesh, hip, levaquin, risperdal
 
Wealthy Most at Risk for Harm by Johnson & Johnson and Subsidiary Products (2016, August 22)
If you make over $100,000 a year, you are far more likely than lower incomes to become a victim of a Johnson & Johnson and/or subsidiary product.
healthcare, cost, co-pay, risk, deductable, insurance, victim, salary
 
Second Quarter 2016 Lawsuits Against Johnson & Johnson Leap Again From 82,200 to 90,700 (2016, August 4)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 90,700.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
Johnson & Johnson Animas Defective Diabetes Devices (2016, August 4)
Gosh and golly gee willikers, yet another Johnson & Johnson subsidiary, Animas, totally sucks, jah?
Johnson and Johnson, Johnson & Johnson, animas, vibe, diabetes, insulin, device, pump
 
Johnson & Johnson Ethicrap, I Mean EthiCON, More JNJ JUNK (2016, July 25)
As I've mentioned, Johnson & Johnson has so many bad products I have to put a bunch in each article now to try to keep up. Now for EthiCON crap.
Johnson and Johnson, Johnson & Johnson, ethicon, harmonic ace, morcellator, physiomesh, secure strap, stapler
 
Johnson and Johnson Janssen Xarelto Slaughter (2016, July 8)
Overstating benefits, downplaying (or not disclosing) risks. Xarelto by Johnson and Johnson Janssen killing people left and right. Over 500 DEAD, 7,100 lawsuits already. Lovely, eh?
false, marketing, death, dead, xarelto, FDA, lawsuit, Janssen
 
This Convinced THREE Juries That Johnson and Johnson Talc Increases Ovarian Cancer (2016, May 14)
One very simple fact convinced THREE juries that Johnson & Johnson talc increases risk of developing ovarian cancer.
Johnson and Johnson, Johnson & Johnson, baby, powder, cancer, lawsuit, ovarian, talc
 
UPDATE: MAY 24, 2012
The FDA showed intelligence for a change and did not approve Xarelto for expanded use according to Yahoo Finance, "FDA panel votes against new use for J&J's Xarelto" The article contains additional information regarding the missing data of the outcome of a 15,000 patient clinical study. One of the FDA reviewers suggested that the missing data may indicate that Xarelto is not effective as J&J claims for expanded use in treating acute coronary syndrome.
 
Original article: Here we go again - another supposed blockbuster drug with issues but will get pushed through FDA anyway. Xarelto is a blood thinner used during major surgeries to reduce the risks of blood clots. It is now being pushed through FDA for regular use to reduce the risk of blood clots in people with acute coronary syndrome. However, due to missing data, "The staff appeared united in the view that the data did not prove Xarelto reduced the risk of death in patients with acute coronary syndrome..." according to Reuters.
 
In the same article, it is clearly stated that 12% of those in clinical trials dropped out. ANNNND - there were three deaths while on the drug that were excluded from information submitted to the FDA. Gee, what's this? If the people in the clinical trial DIE from the drug, they don't count? OMG. No wonder there are so many lawsuits against J&J...
 

According to the available FDA information, Xarelto was not demonstrated to be more effective than currently available drugs - AND has more side effects as well as higher cost.
 
Missing data, 12% dropout rate (or lost track of) and three deaths should be a sure sign that J&J knows there are issues with the drug. In addition, the expectation of such a large number of recipients to total over a billion in sales, although the drug should not be prescribed to those under 18, over 65, anyone with high blood pressure, etc, as well as the known and published side effects - um, how, exactly, could this be a 'blockbuster'? What I see is more off-label marketing to meet the sales goals and more harm with the resulting lawsuits. Oh, joy. Higher health care costs to pay for yet another 'blockbuster'. More like 'economy buster'.
 
Resources:
1. Associated Press (2012, May 23). FDA panel votes against new use for J&J's Xarelto. Yahoo Finance. Retrieved from http://finance.yahoo.com/news/fda-panel-votes-against-j-210934750.html;_ylt=A0LEV1OMeRpU81sAuWNXNyoA;_ylu=X3oDMTEzNWxlYWFhBHNlYwNzcgRwb3MDNwRjb2xvA2JmMQR2dGlkA1NNRTU4OV8x
 
2. Anna Yukhananov (2012, May 21). FDA staff sends mixed message on J&J drug Xarelto. Reuters. Retrieved from http://www.reuters.com/article/2012/05/21/us-fda-johnson-xarelto-idUSBRE84K0M220120521?feedType=RSS&feedName=healthNews&utm_source=twitterfeed&utm_medium=twitter&utm_campaign=Feed%3A+reuters%2FhealthNews+%28Reuters+Health+News%29
 
3. Xarelto Insert (2014, August 28). Xarelto. Drugs.com. Retrieved from http://www.drugs.com/pro/xarelto.html
 
All contents Copyright © 2012-2016 Emily Patterson / Johnson and Toxin. All rights reserved.
 
Web Site and Admin Info:
Home
About
Contact
Disclaimers
Privacy Policy
Site Statistics
Site Resources
Financial Disclosure

 
Recently Posted:
2015 Johnson & Johnson US Lawsuit Update: Jump from 48,500 to 56.500
 
Johnson & Johnson Plans to Expand Healthcare Cost Crisis and Product Liability in Asia
 
Who REALLY Pays for Drug Development? US TAXPAYERS - $21 BILLION for fiscal year 2014
 
Johnson & Johnson Janssen Xarelto Marketed In Violation of FDA Regulations
 
Johnson & Johnson Destroys Thousands of Files Related to Vaginal Mesh
 
Johnson & Johnson: The Global Lawsuit Company


 
 
Most Popular:
The Ever-Growing Number of Lawsuits Against Johnson & Johnson
 
Johnson & Johnson Credo Analysis
 
Johnson & Johnson $4 Billion for DePuy Hip Harm in U.S., With Lawsuits in at Least 4 More Countries